In summary, this rare case of concomitant BRAF V600E‐mutated NSCLC and pleural metastasis of papillary thyroid carcinoma demonstrates the effectiveness of targeted therapy with dabrafenib and trametinib. This evidence concerns the gene BRAF and differentiated thyroid carcinoma.